199 related articles for article (PubMed ID: 21335035)
1. IABS international scientific workshop--Mode of Action of Adjuvants: implications for vaccine safety and design, April 29-30, 2010, Bethesda, MD, USA.
Seemann S; Dodet B
Vaccine; 2011 Apr; 29(17):3340. PubMed ID: 21335035
[No Abstract] [Full Text] [Related]
2. Vaccine adjuvant safety: the elephant in the room.
Petrovsky N
Expert Rev Vaccines; 2013 Jul; 12(7):715-7. PubMed ID: 23885815
[No Abstract] [Full Text] [Related]
3. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes.
Exley C
Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301
[No Abstract] [Full Text] [Related]
4. TLR-based immune adjuvants.
Steinhagen F; Kinjo T; Bode C; Klinman DM
Vaccine; 2011 Apr; 29(17):3341-55. PubMed ID: 20713100
[TBL] [Abstract][Full Text] [Related]
5. Mode of action of adjuvants: implications for vaccine safety and design.
Mastelic B; Ahmed S; Egan WM; Del Giudice G; Golding H; Gust I; Neels P; Reed SG; Sheets RL; Siegrist CA; Lambert PH
Biologicals; 2010 Sep; 38(5):594-601. PubMed ID: 20659806
[TBL] [Abstract][Full Text] [Related]
6. TLR4 agonists as vaccine adjuvants: a chemist's perspective.
Johnson DA
Expert Rev Vaccines; 2013 Jul; 12(7):711-3. PubMed ID: 23885814
[No Abstract] [Full Text] [Related]
7. Are we entering a new age for human vaccine adjuvants?
O'Hagan DT; Fox CB
Expert Rev Vaccines; 2015 Jul; 14(7):909-11. PubMed ID: 25947042
[TBL] [Abstract][Full Text] [Related]
8. Vaccine adjuvants.
Reed SG
Expert Rev Vaccines; 2013 Jul; 12(7):705-6. PubMed ID: 23885812
[No Abstract] [Full Text] [Related]
9. New adjuvanted vaccines in pregnancy: what is known about their safety?
Herberts C; Melgert B; van der Laan JW; Faas M
Expert Rev Vaccines; 2010 Dec; 9(12):1411-22. PubMed ID: 21105777
[TBL] [Abstract][Full Text] [Related]
10. Novel vaccines and adjuvant systems: the utility of animal models for predicting immunogenicity in humans.
Davis HL
Hum Vaccin; 2008; 4(3):246-50. PubMed ID: 18382138
[TBL] [Abstract][Full Text] [Related]
11. The path to a successful vaccine adjuvant--'the long and winding road'.
O'Hagan DT; De Gregorio E
Drug Discov Today; 2009 Jun; 14(11-12):541-51. PubMed ID: 19508916
[TBL] [Abstract][Full Text] [Related]
12. Vaccine adjuvants: in search of new paradigms. Interview by Jenaid Rees.
Petrovsky N
Expert Rev Vaccines; 2013 Jul; 12(7):723-6. PubMed ID: 23885817
[No Abstract] [Full Text] [Related]
13. Nasal vaccine innovation.
Jabbal-Gill I
J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
[TBL] [Abstract][Full Text] [Related]
14. Vaccine adjuvants: smart components to boost the immune system.
Bastola R; Noh G; Keum T; Bashyal S; Seo JE; Choi J; Oh Y; Cho Y; Lee S
Arch Pharm Res; 2017 Nov; 40(11):1238-1248. PubMed ID: 29027637
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvants: insights from industry. Interview by Jenaid Rees.
Andréasson S
Expert Rev Vaccines; 2013 Jul; 12(7):731-2. PubMed ID: 23885818
[No Abstract] [Full Text] [Related]
16. 12th Annual Conference on Vaccine Research.
O'Brien J
Expert Rev Vaccines; 2009 Sep; 8(9):1139-42. PubMed ID: 19722886
[TBL] [Abstract][Full Text] [Related]
17. Combination of adjuvants: the future of vaccine design.
Mount A; Koernig S; Silva A; Drane D; Maraskovsky E; Morelli AB
Expert Rev Vaccines; 2013 Jul; 12(7):733-46. PubMed ID: 23885819
[TBL] [Abstract][Full Text] [Related]
18. Survey of human-use adjuvants.
Kenney RT; Edelman R
Expert Rev Vaccines; 2003 Apr; 2(2):167-88. PubMed ID: 12899569
[TBL] [Abstract][Full Text] [Related]
19. Immunology of vaccine adjuvants.
Ribeiro CM; Schijns VE
Methods Mol Biol; 2010; 626():1-14. PubMed ID: 20099117
[TBL] [Abstract][Full Text] [Related]
20. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
